Johnson & Johnson (JNJ) Reports 100% Success in OMNY-AF Study

Johnson & Johnson (NYSE:JNJ) is among the most profitable mega cap stocks to buy. On February 6, Johnson & Johnson (NYSE:JNJ) disclosed 12-month pilot-phase data from the OMNY-AF study, which examined the investigational OMNYPULSE Platform for the treatment of symptomatic paroxysmal atrial fibrillation (AFib). Announced during the 31st Annual AF Symposium in Boston, the results reveal that investigators achieved 100% acute procedural success with zero adverse events linked to the procedure.

As stated by Dinesh Sharma, M.D., Section Head of Cardiac Electrophysiology at the Naples Heart Institute,

“The 12-month data provide encouraging early evidence on the OMNY-AF study with promising safety outcomes – no procedure-related adverse events or MRI-detected cerebral lesions – across eight centers in the pilot phase.”

Jim Cramer Couldn't Stop Gushing About Johnson & Johnson (JNJ)'s Cancer Drugs

Trong Nguyen / Shutterstock.com

Earlier on February 3, RBC Capital increased the price target on Johnson & Johnson (NYSE:JNJ) to $255 from $240 and reiterated an Outperform rating following investor questions about the Daubert decision related to talc litigation and how it will impact the company financially.

According to the firm’s analysis, Johnson & Johnson (NYSE:JNJ) is unlikely to overturn the key consequences of the Daubert ruling, but the case may continue for years. Despite this, the firm remains confident in the healthcare giant’s financial position, given its strong performance, which helps reduce risk.

Johnson & Johnson (NYSE:JNJ) is a global healthcare company focused on innovative medicines and medical technologies. Headquartered in New Jersey, the company serves a wide clientele, including retailers, wholesalers, healthcare professionals, and hospitals.

While we acknowledge the potential of JNJ to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than JNJ and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money.

Disclosure: None.